SANGAMO THERAPEUTICS INC's ticker is SGMO and the CUSIP is 800677106. A total of 1 filers reported holding SANGAMO THERAPEUTICS INC in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $7,855 | -53.9% | 13,096 | 0.0% | 0.00% | – |
Q2 2023 | $17,025 | -68.8% | 13,096 | -57.8% | 0.00% | – |
Q1 2023 | $54,584 | -70.9% | 31,013 | -48.0% | 0.00% | – |
Q4 2022 | $187,351 | -31.6% | 59,666 | +6.7% | 0.00% | – |
Q3 2022 | $274,000 | +25.7% | 55,922 | +6.6% | 0.00% | – |
Q2 2022 | $218,000 | -30.4% | 52,447 | -2.6% | 0.00% | – |
Q1 2022 | $313,000 | -22.7% | 53,860 | -0.4% | 0.00% | – |
Q4 2021 | $405,000 | -16.5% | 54,091 | +0.5% | 0.00% | – |
Q3 2021 | $485,000 | +35.9% | 53,820 | +80.0% | 0.00% | – |
Q2 2021 | $357,000 | -5.1% | 29,908 | -0.2% | 0.00% | – |
Q1 2021 | $376,000 | -11.7% | 29,956 | +9.8% | 0.00% | – |
Q4 2020 | $426,000 | +63.8% | 27,272 | -0.6% | 0.00% | – |
Q3 2020 | $260,000 | -10.3% | 27,441 | -15.1% | 0.00% | – |
Q2 2020 | $290,000 | +47.2% | 32,308 | +4.7% | 0.00% | – |
Q1 2020 | $197,000 | -34.6% | 30,866 | -14.2% | 0.00% | – |
Q4 2019 | $301,000 | +2.0% | 35,985 | +10.2% | 0.00% | – |
Q3 2019 | $295,000 | +17.1% | 32,655 | +39.4% | 0.00% | – |
Q2 2019 | $252,000 | +29.2% | 23,425 | +14.6% | 0.00% | – |
Q1 2019 | $195,000 | -6.2% | 20,445 | +13.2% | 0.00% | – |
Q4 2018 | $208,000 | -25.7% | 18,066 | +9.3% | 0.00% | – |
Q3 2018 | $280,000 | +19.1% | 16,532 | 0.0% | 0.00% | – |
Q2 2018 | $235,000 | -20.1% | 16,532 | +6.8% | 0.00% | – |
Q1 2018 | $294,000 | -16.9% | 15,483 | -27.5% | 0.00% | – |
Q4 2017 | $354,000 | +10.3% | 21,358 | -1.5% | 0.00% | – |
Q3 2017 | $321,000 | +92.2% | 21,677 | +15.5% | 0.00% | – |
Q2 2017 | $167,000 | +79.6% | 18,774 | 0.0% | 0.00% | – |
Q1 2017 | $93,000 | +63.2% | 18,774 | 0.0% | 0.00% | – |
Q4 2016 | $57,000 | -6.6% | 18,774 | +41.5% | 0.00% | – |
Q3 2016 | $61,000 | -19.7% | 13,267 | 0.0% | 0.00% | – |
Q2 2016 | $76,000 | -2.6% | 13,267 | 0.0% | 0.00% | – |
Q1 2016 | $78,000 | -18.8% | 13,267 | +27.3% | 0.00% | – |
Q4 2015 | $96,000 | +71.4% | 10,419 | 0.0% | 0.00% | – |
Q3 2015 | $56,000 | -49.5% | 10,419 | 0.0% | 0.00% | – |
Q2 2015 | $111,000 | -33.1% | 10,419 | 0.0% | 0.00% | – |
Q1 2015 | $166,000 | +3.8% | 10,419 | 0.0% | 0.00% | – |
Q4 2014 | $160,000 | +39.1% | 10,419 | 0.0% | 0.00% | – |
Q3 2014 | $115,000 | – | 10,419 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Alexandria Capital, LLC | 916,153 | $8,740,000 | 1.27% |
Casdin Capital, LLC | 1,080,000 | $10,303,000 | 1.13% |
Rhenman & Partners Asset Management AB | 843,957 | $8,051,000 | 0.94% |
WASATCH ADVISORS LP | 6,437,908 | $61,418,000 | 0.67% |
BB BIOTECH AG | 2,650,000 | $25,281,000 | 0.64% |
Trellus Management Company, LLC | 30,000 | $286,000 | 0.54% |
Opus Point Partners Management, LLC | 33,529 | $320,000 | 0.43% |
SECTOR GAMMA AS | 238,857 | $2,279,000 | 0.36% |
Leisure Capital Management | 37,656 | $359,000 | 0.30% |
Ceeto Capital Group, LLC | 41,000 | $391,000 | 0.29% |